JP2011144177A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2011144177A5 JP2011144177A5 JP2011023799A JP2011023799A JP2011144177A5 JP 2011144177 A5 JP2011144177 A5 JP 2011144177A5 JP 2011023799 A JP2011023799 A JP 2011023799A JP 2011023799 A JP2011023799 A JP 2011023799A JP 2011144177 A5 JP2011144177 A5 JP 2011144177A5
- Authority
- JP
- Japan
- Prior art keywords
- protein
- soluble
- pharmaceutical composition
- amino acid
- seq
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 102100035793 CD83 antigen Human genes 0.000 claims 46
- 101000946856 Homo sapiens CD83 antigen Proteins 0.000 claims 46
- 239000008194 pharmaceutical composition Substances 0.000 claims 26
- 108020004707 nucleic acids Proteins 0.000 claims 21
- 102000039446 nucleic acids Human genes 0.000 claims 21
- 150000007523 nucleic acids Chemical class 0.000 claims 21
- 125000000539 amino acid group Chemical group 0.000 claims 20
- FWMNVWWHGCHHJJ-SKKKGAJSSA-N 4-amino-1-[(2r)-6-amino-2-[[(2r)-2-[[(2r)-2-[[(2r)-2-amino-3-phenylpropanoyl]amino]-3-phenylpropanoyl]amino]-4-methylpentanoyl]amino]hexanoyl]piperidine-4-carboxylic acid Chemical compound C([C@H](C(=O)N[C@H](CC(C)C)C(=O)N[C@H](CCCCN)C(=O)N1CCC(N)(CC1)C(O)=O)NC(=O)[C@H](N)CC=1C=CC=CC=1)C1=CC=CC=C1 FWMNVWWHGCHHJJ-SKKKGAJSSA-N 0.000 claims 15
- 125000000151 cysteine group Chemical class N[C@@H](CS)C(=O)* 0.000 claims 11
- 210000004027 cell Anatomy 0.000 claims 10
- 239000013598 vector Substances 0.000 claims 9
- 230000024932 T cell mediated immunity Effects 0.000 claims 8
- 210000001744 T-lymphocyte Anatomy 0.000 claims 8
- 210000003719 b-lymphocyte Anatomy 0.000 claims 8
- 210000004443 dendritic cell Anatomy 0.000 claims 8
- 201000010099 disease Diseases 0.000 claims 8
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims 8
- 230000004064 dysfunction Effects 0.000 claims 8
- 239000000178 monomer Substances 0.000 claims 8
- 235000018102 proteins Nutrition 0.000 claims 8
- 102000004169 proteins and genes Human genes 0.000 claims 8
- 108090000623 proteins and genes Proteins 0.000 claims 8
- 238000011282 treatment Methods 0.000 claims 7
- MTCFGRXMJLQNBG-UHFFFAOYSA-N Serine Natural products OCC(N)C(O)=O MTCFGRXMJLQNBG-UHFFFAOYSA-N 0.000 claims 6
- DHMQDGOQFOQNFH-UHFFFAOYSA-N Glycine Chemical compound NCC(O)=O DHMQDGOQFOQNFH-UHFFFAOYSA-N 0.000 claims 5
- 230000002265 prevention Effects 0.000 claims 5
- 206010002556 Ankylosing Spondylitis Diseases 0.000 claims 4
- 235000001014 amino acid Nutrition 0.000 claims 4
- 229940024606 amino acid Drugs 0.000 claims 4
- 150000001413 amino acids Chemical class 0.000 claims 4
- 239000012634 fragment Substances 0.000 claims 4
- 238000004519 manufacturing process Methods 0.000 claims 4
- 239000000539 dimer Substances 0.000 claims 3
- 239000013604 expression vector Substances 0.000 claims 3
- 238000003259 recombinant expression Methods 0.000 claims 3
- 208000030507 AIDS Diseases 0.000 claims 2
- 208000023275 Autoimmune disease Diseases 0.000 claims 2
- 208000011231 Crohn disease Diseases 0.000 claims 2
- 108020004414 DNA Proteins 0.000 claims 2
- 241000588724 Escherichia coli Species 0.000 claims 2
- 239000004471 Glycine Substances 0.000 claims 2
- 206010020751 Hypersensitivity Diseases 0.000 claims 2
- QNAYBMKLOCPYGJ-REOHCLBHSA-N L-alanine Chemical compound C[C@H](N)C(O)=O QNAYBMKLOCPYGJ-REOHCLBHSA-N 0.000 claims 2
- 206010028372 Muscular weakness Diseases 0.000 claims 2
- 206010033799 Paralysis Diseases 0.000 claims 2
- 201000004681 Psoriasis Diseases 0.000 claims 2
- 206010067584 Type 1 diabetes mellitus Diseases 0.000 claims 2
- 206010047115 Vasculitis Diseases 0.000 claims 2
- 235000004279 alanine Nutrition 0.000 claims 2
- 208000026935 allergic disease Diseases 0.000 claims 2
- 230000007815 allergy Effects 0.000 claims 2
- 208000006673 asthma Diseases 0.000 claims 2
- 230000001363 autoimmune Effects 0.000 claims 2
- 230000001684 chronic effect Effects 0.000 claims 2
- 206010009887 colitis Diseases 0.000 claims 2
- 238000012258 culturing Methods 0.000 claims 2
- 235000018417 cysteine Nutrition 0.000 claims 2
- 239000000710 homodimer Substances 0.000 claims 2
- 230000003834 intracellular effect Effects 0.000 claims 2
- 238000000034 method Methods 0.000 claims 2
- 201000006417 multiple sclerosis Diseases 0.000 claims 2
- 230000036473 myasthenia Effects 0.000 claims 2
- 210000000056 organ Anatomy 0.000 claims 2
- 238000011321 prophylaxis Methods 0.000 claims 2
- 206010039073 rheumatoid arthritis Diseases 0.000 claims 2
- 125000003607 serino group Chemical group [H]N([H])[C@]([H])(C(=O)[*])C(O[H])([H])[H] 0.000 claims 2
- 208000017520 skin disease Diseases 0.000 claims 2
- 208000011580 syndromic disease Diseases 0.000 claims 2
- 201000000596 systemic lupus erythematosus Diseases 0.000 claims 2
- MTCFGRXMJLQNBG-REOHCLBHSA-N (2S)-2-Amino-3-hydroxypropansäure Chemical compound OC[C@H](N)C(O)=O MTCFGRXMJLQNBG-REOHCLBHSA-N 0.000 claims 1
- 108091032973 (ribonucleotides)n+m Proteins 0.000 claims 1
- 239000004475 Arginine Substances 0.000 claims 1
- DCXYFEDJOCDNAF-UHFFFAOYSA-N Asparagine Natural products OC(=O)C(N)CC(N)=O DCXYFEDJOCDNAF-UHFFFAOYSA-N 0.000 claims 1
- 206010009900 Colitis ulcerative Diseases 0.000 claims 1
- WHUUTDBJXJRKMK-UHFFFAOYSA-N Glutamic acid Natural products OC(=O)C(N)CCC(O)=O WHUUTDBJXJRKMK-UHFFFAOYSA-N 0.000 claims 1
- 208000022559 Inflammatory bowel disease Diseases 0.000 claims 1
- ODKSFYDXXFIFQN-BYPYZUCNSA-P L-argininium(2+) Chemical compound NC(=[NH2+])NCCC[C@H]([NH3+])C(O)=O ODKSFYDXXFIFQN-BYPYZUCNSA-P 0.000 claims 1
- DCXYFEDJOCDNAF-REOHCLBHSA-N L-asparagine Chemical compound OC(=O)[C@@H](N)CC(N)=O DCXYFEDJOCDNAF-REOHCLBHSA-N 0.000 claims 1
- CKLJMWTZIZZHCS-REOHCLBHSA-N L-aspartic acid Chemical compound OC(=O)[C@@H](N)CC(O)=O CKLJMWTZIZZHCS-REOHCLBHSA-N 0.000 claims 1
- WHUUTDBJXJRKMK-VKHMYHEASA-N L-glutamic acid Chemical compound OC(=O)[C@@H](N)CCC(O)=O WHUUTDBJXJRKMK-VKHMYHEASA-N 0.000 claims 1
- ZDXPYRJPNDTMRX-VKHMYHEASA-N L-glutamine Chemical compound OC(=O)[C@@H](N)CCC(N)=O ZDXPYRJPNDTMRX-VKHMYHEASA-N 0.000 claims 1
- HNDVDQJCIGZPNO-YFKPBYRVSA-N L-histidine Chemical compound OC(=O)[C@@H](N)CC1=CN=CN1 HNDVDQJCIGZPNO-YFKPBYRVSA-N 0.000 claims 1
- KDXKERNSBIXSRK-YFKPBYRVSA-N L-lysine Chemical compound NCCCC[C@H](N)C(O)=O KDXKERNSBIXSRK-YFKPBYRVSA-N 0.000 claims 1
- AYFVYJQAPQTCCC-GBXIJSLDSA-N L-threonine Chemical compound C[C@@H](O)[C@H](N)C(O)=O AYFVYJQAPQTCCC-GBXIJSLDSA-N 0.000 claims 1
- OUYCCCASQSFEME-QMMMGPOBSA-N L-tyrosine Chemical compound OC(=O)[C@@H](N)CC1=CC=C(O)C=C1 OUYCCCASQSFEME-QMMMGPOBSA-N 0.000 claims 1
- KZSNJWFQEVHDMF-BYPYZUCNSA-N L-valine Chemical compound CC(C)[C@H](N)C(O)=O KZSNJWFQEVHDMF-BYPYZUCNSA-N 0.000 claims 1
- KDXKERNSBIXSRK-UHFFFAOYSA-N Lysine Natural products NCCCCC(N)C(O)=O KDXKERNSBIXSRK-UHFFFAOYSA-N 0.000 claims 1
- 239000004472 Lysine Substances 0.000 claims 1
- 241000124008 Mammalia Species 0.000 claims 1
- 206010053395 Progressive multiple sclerosis Diseases 0.000 claims 1
- 108091081024 Start codon Proteins 0.000 claims 1
- AYFVYJQAPQTCCC-UHFFFAOYSA-N Threonine Natural products CC(O)C(N)C(O)=O AYFVYJQAPQTCCC-UHFFFAOYSA-N 0.000 claims 1
- 239000004473 Threonine Substances 0.000 claims 1
- 206010052779 Transplant rejections Diseases 0.000 claims 1
- 208000025865 Ulcer Diseases 0.000 claims 1
- 201000006704 Ulcerative Colitis Diseases 0.000 claims 1
- KZSNJWFQEVHDMF-UHFFFAOYSA-N Valine Natural products CC(C)C(N)C(O)=O KZSNJWFQEVHDMF-UHFFFAOYSA-N 0.000 claims 1
- 239000000427 antigen Substances 0.000 claims 1
- 102000036639 antigens Human genes 0.000 claims 1
- 108091007433 antigens Proteins 0.000 claims 1
- ODKSFYDXXFIFQN-UHFFFAOYSA-N arginine Natural products OC(=O)C(N)CCCNC(N)=N ODKSFYDXXFIFQN-UHFFFAOYSA-N 0.000 claims 1
- 235000009582 asparagine Nutrition 0.000 claims 1
- 229960001230 asparagine Drugs 0.000 claims 1
- 235000003704 aspartic acid Nutrition 0.000 claims 1
- OQFSQFPPLPISGP-UHFFFAOYSA-N beta-carboxyaspartic acid Natural products OC(=O)C(N)C(C(O)=O)C(O)=O OQFSQFPPLPISGP-UHFFFAOYSA-N 0.000 claims 1
- XUJNEKJLAYXESH-UHFFFAOYSA-N cysteine Natural products SCC(N)C(O)=O XUJNEKJLAYXESH-UHFFFAOYSA-N 0.000 claims 1
- 230000003828 downregulation Effects 0.000 claims 1
- 235000013922 glutamic acid Nutrition 0.000 claims 1
- 239000004220 glutamic acid Substances 0.000 claims 1
- ZDXPYRJPNDTMRX-UHFFFAOYSA-N glutamine Natural products OC(=O)C(N)CCC(N)=O ZDXPYRJPNDTMRX-UHFFFAOYSA-N 0.000 claims 1
- 230000013595 glycosylation Effects 0.000 claims 1
- 238000006206 glycosylation reaction Methods 0.000 claims 1
- HNDVDQJCIGZPNO-UHFFFAOYSA-N histidine Natural products OC(=O)C(N)CC1=CN=CN1 HNDVDQJCIGZPNO-UHFFFAOYSA-N 0.000 claims 1
- 230000002757 inflammatory effect Effects 0.000 claims 1
- 239000002773 nucleotide Substances 0.000 claims 1
- 125000003729 nucleotide group Chemical group 0.000 claims 1
- 238000007920 subcutaneous administration Methods 0.000 claims 1
- 238000007910 systemic administration Methods 0.000 claims 1
- 208000035408 type 1 diabetes mellitus 1 Diseases 0.000 claims 1
- OUYCCCASQSFEME-UHFFFAOYSA-N tyrosine Natural products OC(=O)C(N)CC1=CC=C(O)C=C1 OUYCCCASQSFEME-UHFFFAOYSA-N 0.000 claims 1
- 239000004474 valine Substances 0.000 claims 1
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP02025851.3 | 2002-11-19 | ||
| EP02025851A EP1422241A1 (en) | 2002-11-19 | 2002-11-19 | Use of soluble forms of CD83 and nucleic acids encoding them for the treatment or prevention of diseases |
Related Parent Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2004552655A Division JP4740595B2 (ja) | 2002-11-19 | 2003-11-19 | 疾患の治療または予防のための可溶型ｃｄ８３タンパク質およびそれをコードする核酸の使用 |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2014090480A Division JP5878584B2 (ja) | 2002-11-19 | 2014-04-24 | 疾患の治療または予防のための可溶型ｃｄ８３タンパク質およびそれをコードする核酸の使用 |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2011144177A JP2011144177A (ja) | 2011-07-28 |
| JP2011144177A5 true JP2011144177A5 (enExample) | 2012-06-21 |
| JP5557765B2 JP5557765B2 (ja) | 2014-07-23 |
Family
ID=32187165
Family Applications (3)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2004552655A Expired - Lifetime JP4740595B2 (ja) | 2002-11-19 | 2003-11-19 | 疾患の治療または予防のための可溶型ｃｄ８３タンパク質およびそれをコードする核酸の使用 |
| JP2011023799A Expired - Lifetime JP5557765B2 (ja) | 2002-11-19 | 2011-02-07 | 疾患の治療または予防のための可溶型ｃｄ８３タンパク質およびそれをコードする核酸の使用 |
| JP2014090480A Expired - Lifetime JP5878584B2 (ja) | 2002-11-19 | 2014-04-24 | 疾患の治療または予防のための可溶型ｃｄ８３タンパク質およびそれをコードする核酸の使用 |
Family Applications Before (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2004552655A Expired - Lifetime JP4740595B2 (ja) | 2002-11-19 | 2003-11-19 | 疾患の治療または予防のための可溶型ｃｄ８３タンパク質およびそれをコードする核酸の使用 |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2014090480A Expired - Lifetime JP5878584B2 (ja) | 2002-11-19 | 2014-04-24 | 疾患の治療または予防のための可溶型ｃｄ８３タンパク質およびそれをコードする核酸の使用 |
Country Status (9)
| Country | Link |
|---|---|
| US (3) | US7893200B2 (enExample) |
| EP (5) | EP1422241A1 (enExample) |
| JP (3) | JP4740595B2 (enExample) |
| AU (1) | AU2003292045A1 (enExample) |
| CA (2) | CA2507373C (enExample) |
| DK (1) | DK1562985T3 (enExample) |
| ES (2) | ES2534308T3 (enExample) |
| SI (1) | SI1562985T1 (enExample) |
| WO (1) | WO2004046182A2 (enExample) |
Families Citing this family (13)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP1422241A1 (en) | 2002-11-19 | 2004-05-26 | Alexander Steinkasserer | Use of soluble forms of CD83 and nucleic acids encoding them for the treatment or prevention of diseases |
| US9102726B2 (en) | 2002-12-04 | 2015-08-11 | Argos Therapeutics, Inc. | Nucleic acid of recombination expression vector encoding soluble forms of CD83, host cells transformed/transfected therewith and pharmaceutical compositions containing same |
| US7169898B2 (en) | 2002-12-04 | 2007-01-30 | Alexander Steinkasserer | Soluble CD83 proteins and use thereof for the treatment or prevention of a disease or medical condition caused by dysfunction or undesired function of a cellular immune response involving T cells |
| CN101484461B (zh) | 2006-08-18 | 2014-09-17 | 阿哥斯医疗公司 | Cd83在联合治疗中的用途 |
| EP2254998B1 (en) | 2008-02-28 | 2015-12-23 | Argos Therapeutics, Inc. | Transient expression of immunomodulatory polypeptides for the prevention and treatment of autoimmune disease, allergy and transplant rejection |
| JP2011520959A (ja) * | 2008-05-23 | 2011-07-21 | アルゴス・セラピューティクス・インコーポレーテッド | 新規可溶性ｃｄ８３ポリペプチド、配合物および使用法 |
| US20120322085A1 (en) * | 2009-11-05 | 2012-12-20 | Osaka University | Therapeutic agent for autoimmune diseases or allergy, and method for screening for the therapeutic agent |
| CN104610452B (zh) * | 2015-01-27 | 2018-11-20 | 中国科学技术大学先进技术研究院 | 抗人cd83单克隆抗体及其制备、鉴定和应用 |
| EP3318577A4 (en) | 2015-06-30 | 2019-01-23 | Osaka University | ANTIPLEXIN A1 AGONISTANTIKÖRPER |
| WO2018085617A1 (en) | 2016-11-07 | 2018-05-11 | Argos Therapeutics, Inc. | Bispecific antibodies that modulate tlr-4 signaling and uses thereof |
| WO2018143911A1 (en) | 2017-01-31 | 2018-08-09 | Kimberly-Clark Worldwide, Inc. | Antibacterial composition including benzoic acid ester and methods of inhibiting bacterial growth utilizing the same |
| EP3895723A1 (en) | 2020-04-16 | 2021-10-20 | Friedrich-Alexander-Universität Erlangen-Nürnberg | Scd83 for wound healing, hair growth, and skin and hair care |
| DE102024110866A1 (de) * | 2024-04-18 | 2025-10-23 | Christian Arnold | Pharmazeutische Zusammensetzung zur Heilung einer Wunde |
Family Cites Families (17)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5710262A (en) | 1992-04-17 | 1998-01-20 | Dana-Faber Cancer Institute, Inc. | Nucleic acid encoding HB15 polypeptides |
| US5316920A (en) * | 1992-04-17 | 1994-05-31 | Dana-Faber Cancer Institute, Inc. | Lymphocyte activation antigen HB15, a member of the immunoglobulin superfamily |
| AU2273397A (en) * | 1996-02-15 | 1997-09-02 | Immunex Corporation | Methods and compositions for modulating an immune response |
| ATE324443T1 (de) | 1997-08-26 | 2006-05-15 | Zymogenetics Inc | Für adipozyten spezifische protein homologe |
| HK1043312B (en) | 1999-05-07 | 2006-07-28 | Genentech, Inc. | Treatment of autoimmune diseases with antagonists which bind to b cell surface markers |
| GB2370273A (en) | 2000-12-20 | 2002-06-26 | Viaxxel Biotech Gmbh | Compounds that affect CD83 expression |
| WO2003033011A2 (en) * | 2001-10-18 | 2003-04-24 | Zlatko Ademovic | Repetitive motifs from salivary proline rich proteins, mucin and collagen |
| JP2005519586A (ja) | 2001-11-21 | 2005-07-07 | セルテック アール アンド ディー， インコーポレイテッド | Ｃｄ８３遺伝子産物を利用したサイトカイン・レベルの操作法 |
| US20040185040A1 (en) | 2001-11-21 | 2004-09-23 | Celltech R & D Limited | Modulating immune responses |
| US6652537B2 (en) | 2001-12-12 | 2003-11-25 | C. R. Bard, Inc. | Articulating stone basket |
| US20030219436A1 (en) | 2002-03-15 | 2003-11-27 | Ledbetter Jeffrey A. | Compositions and methods to regulate an immune response using CD83 gene expressed in tumors and using soluble CD83-Ig fusion protein |
| AU2002950779A0 (en) | 2002-08-15 | 2002-09-12 | The Corporation Of The Trustees Of The Order Of The Sisters Of Mercy In Queensland | A method of immunomodulation |
| JP2006503110A (ja) | 2002-10-09 | 2006-01-26 | トーラーレックス， インク． | エフェクタｔ細胞または制御性ｔ細胞に選択的に結合する分子およびその使用方法 |
| EP1422241A1 (en) | 2002-11-19 | 2004-05-26 | Alexander Steinkasserer | Use of soluble forms of CD83 and nucleic acids encoding them for the treatment or prevention of diseases |
| US7169898B2 (en) | 2002-12-04 | 2007-01-30 | Alexander Steinkasserer | Soluble CD83 proteins and use thereof for the treatment or prevention of a disease or medical condition caused by dysfunction or undesired function of a cellular immune response involving T cells |
| US9102726B2 (en) | 2002-12-04 | 2015-08-11 | Argos Therapeutics, Inc. | Nucleic acid of recombination expression vector encoding soluble forms of CD83, host cells transformed/transfected therewith and pharmaceutical compositions containing same |
| JP2011520959A (ja) | 2008-05-23 | 2011-07-21 | アルゴス・セラピューティクス・インコーポレーテッド | 新規可溶性ｃｄ８３ポリペプチド、配合物および使用法 |
-
2002
- 2002-11-19 EP EP02025851A patent/EP1422241A1/en not_active Withdrawn
-
2003
- 2003-11-19 DK DK03767573.3T patent/DK1562985T3/da active
- 2003-11-19 US US10/535,522 patent/US7893200B2/en active Active
- 2003-11-19 SI SI200332422T patent/SI1562985T1/sl unknown
- 2003-11-19 EP EP15195041.7A patent/EP3031824A1/en not_active Withdrawn
- 2003-11-19 EP EP10188586A patent/EP2345670B1/en not_active Expired - Lifetime
- 2003-11-19 AU AU2003292045A patent/AU2003292045A1/en not_active Abandoned
- 2003-11-19 ES ES03767573.3T patent/ES2534308T3/es not_active Expired - Lifetime
- 2003-11-19 EP EP03767573.3A patent/EP1562985B1/en not_active Expired - Lifetime
- 2003-11-19 ES ES10188586T patent/ES2413631T3/es not_active Expired - Lifetime
- 2003-11-19 CA CA2507373A patent/CA2507373C/en not_active Expired - Lifetime
- 2003-11-19 JP JP2004552655A patent/JP4740595B2/ja not_active Expired - Lifetime
- 2003-11-19 EP EP13189881.9A patent/EP2692733B1/en not_active Expired - Lifetime
- 2003-11-19 WO PCT/EP2003/012941 patent/WO2004046182A2/en not_active Ceased
- 2003-11-19 CA CA2847795A patent/CA2847795C/en not_active Expired - Lifetime
-
2011
- 2011-01-21 US US13/011,380 patent/US8759505B2/en not_active Expired - Lifetime
- 2011-02-07 JP JP2011023799A patent/JP5557765B2/ja not_active Expired - Lifetime
-
2014
- 2014-04-24 JP JP2014090480A patent/JP5878584B2/ja not_active Expired - Lifetime
- 2014-06-17 US US14/306,712 patent/US9732140B2/en not_active Expired - Fee Related
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2011144177A5 (enExample) | ||
| JP2022058337A (ja) | 自己免疫疾患の治療のために制御性ｔ細胞を選択的に活性化する分子 | |
| KR102493543B1 (ko) | 자가면역 질환의 치료를 위한 조절 t 세포를 선택적으로 활성화시키는 분자 | |
| JP2015212284A5 (enExample) | ||
| JP2007530435A5 (enExample) | ||
| KR102483242B1 (ko) | Mg53 돌연변이체, 및 그의 제조 방법 및 그의 용도 | |
| JP2014513953A5 (enExample) | ||
| EP2470556A1 (en) | Il-17 binding compounds and medical uses thereof | |
| RU2010122053A (ru) | Иммуносупрессорные полипептиды и нуклеиновые кислоты | |
| Huo et al. | Functional characterization of interleukin (IL)-22 and its inhibitor, IL-22 binding protein (IL-22BP) in Mandarin fish, Siniperca chuatsi | |
| JP2008507298A5 (enExample) | ||
| PT1873166E (pt) | Dímeros de sgp130fc melhorados | |
| JP2014510519A5 (enExample) | ||
| JP2006523432A5 (enExample) | ||
| JP2015511599A5 (enExample) | ||
| JP2019520058A5 (enExample) | ||
| JP2010535488A (ja) | インターフェロン融合タンパク質 | |
| JPH0690781A (ja) | Ｂ型肝炎ウイルス表面抗原の製造法 | |
| JP2015524413A5 (enExample) | ||
| CN104974262B (zh) | 重组双功能融合蛋白及其制法和用途 | |
| IL298626A (en) | Cytokine conjugates | |
| JP2025521602A (ja) | 炎症状態および自己免疫状態を処置するための方法および組成物 | |
| CN102030822A (zh) | 人类新细胞因子VSTM1-v2及其应用 | |
| JP2013529900A5 (enExample) | ||
| WO2011147320A1 (zh) | B细胞激活因子拮抗剂及其制备方法与用途 |